Dyadic International, Inc. (DYAI) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Jupiter, FL, United States. Der aktuelle CEO ist Mark A. Emalfarb.
DYAI hat IPO-Datum 2008-01-16, 6 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $31.7M.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
